VYZULTA achieved the primary objective:
noninferiority to timolol 0.5% at all tested time points1,2

Mean IOP reduction of 7.5 to 9.1 mmHg from baseline with VYZULTA3

VYZULTA demonstrated superior IOP reduction vs timolol 0.5% at Month 33

In APOLLO, baseline mean diurnal IOP was 26.7 mmHg and 26.5 mmHg in patients randomized to VYZULTA and timolol 0.5%, respectively1

Apollo Study Chart

Please swipe to see more data

In LUNAR, baseline mean diurnal IOP was 26.6 mmHg and 26.4 mmHg in patients randomized to VYZULTA and timolol 0.5%, respectively2

Lunar Study Chart

Please swipe to see more data

 

Learn about the APOLLO & LUNAR studies
with Dr. Radcliffe, Dr. Mosaed, and Dr. Al-Aswad

Learn about the APOLLO & LUNAR studies with Dr. Radcliffe, Dr. Mosaed, and Dr. Al-Aswad

VYZULTA (LBN 0.024%) demonstrated statistically significant greater mean IOP reduction compared with XALATAN (latanoprost) 0.005% at Day 285

In the VOYAGER dose-ranging study, VYZULTA (LBN 0.024%) lowered mean diurnal IOP by 1.23 mmHg more than XALATAN (latanoprost) 0.005% at day 285

42% of patients achieved a reduction of at least 2 mmHg more than the mean diurnal IOP reduction for XALATAN (latanoprost) 0.005%5
— Post-hoc analysis. XALATAN (latanoprost) 0.005% mean diurnal IOP reduction of 7.8 mmHg

IOP reduction from baseline at Day 28:

VYZULTA (LBN 0.024%) = 34.6%

XALATAN (latanoprost) 0.005% = 29.8%

 

Baseline mean diurnal IOP:

› VYZULTA (LBN 0.024%) = 26.01 mmHg

› XALATAN (latanoprost) 0.005% = 26.15 mmHg

Voyager study design voyager study design
Voyager study design

Learn about the VOYAGER study with Dr. Bacharach

Learn about the VOYAGER study with Dr. Bacharach

 

VYZULTA achieved long-term IOP reduction in patients with low baseline IOP6

In the long-term JUPITER study, treatment with VYZULTA resulted in a statistically significant reduced mean IOP of 14.4 mmHg at 12 months6

VYZULTA IOP reduction from baseline

26.5%

› Majority of patients had baseline IOP ≤21.0 mmHg

P <0.001 at all measurements

Jupiter study design jupiter study design
Jupiter study design

Learn about the JUPITER study with Dr. Teymoorian

Learn about the JUPITER study with Dr. Teymoorian

VYZULTA has a demonstrated safety profile

› Less than 1% discontinuation due to ocular adverse reactions1

› Approximately 0.6% of patients discontinued VYZULTA therapy due to ocular adverse reactions

› The most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)3

INDICATION

VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION 
  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)
1. Weinreb RN, Sforzolini BS, Vittitow J, Liebmann J. Latanoprostene bu nod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016;123(5):965-973.
2. Medeiros FA, Martin KR, Peace J, Sforzolini BS, Vittitow JL, Weinreb RN. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study. Am J Ophthalmol. 2016;168:250-259.
3. VYZULTA Prescribing Information. Bausch & Lomb Incorporated. 2018.
4. Data on File. Bausch & Lomb Incorporated.
5. Weinreb RN, Ong T, Scassellati SB, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738-745.
6. Kawase K, Vittitow JL, Weinreb RN, Araie M. Long-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subJects with open-angle glaucoma or ocular hypertension: the JUPITER study. Adv Ther. 2016;33(9):1612-1627.

SEE MORE

INDICATION

VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION 
  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation